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The presence of metastases in lymph nodes is the most powerful prognostic factor in breast cancer patients. Routine histological
examination of lymph nodes has limited sensitivity for the detection of breast cancer metastases. The aim of the present study was to
develop a multimarker reverse transcriptase–polymerase chain reaction (RT—PCR) assay for the detection of minimal residual
disease in sentinel nodes of breast cancer patients. RNA was extracted from 30 sentinel lymph nodes (SLN) obtained from 28
patients, three primary breast cancers (positive controls), three lymph nodes from patients with benign diseases, and peripheral blood
lymphocytes of 10 healthy volunteers (negative controls). RT–PCR was performed using the following markers; cytokeratin (CK)-19,
NY-BR-1 and mammaglobin B. RT–PCR results were compared to enhanced histopathologic examination and immunohistochem-
istry (IHC). All three positive controls showed strong PCR amplification for all three markers. None of the 13 negative controls was
amplified by any of the three markers. Among the 30 SLN analysed, breast cancer metastases were detected in six SLNs by routine
histology, in eight by IHC and in 15 by RT–PCR. We conclude that a multimarker RT–PCR assay probing for NY-BR-1,
mammaglobin-B, and CK-19 is more sensitive compared to enhanced pathologic examination. This method may prove to be of value
in breast cancer staging and prognosis evaluation.
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Although up to 80% of breast cancer patients are identified at an
early stage when disease is apparently localised, 30–35% of node-
negative patients will develop clinically detectable distant metas-
tases within 5 years of treatment of the primary breast carcinoma
and ultimately suffer tumour-related mortality (Nemoto et al,
1980). Routine histological examination of lymph nodes has
limited sensitivity for the detection of breast cancer metastases. It
is usually performed with a single haematoxilyn and eosin (H&E)-
stained section through the examined node and therefore small
metastases can go undetected. In a landmark study conducted by
the International (Ludwig) Breast Cancer Group (International
(Ludwig) Breast Cancer Study Group, 1990), serial sectioning of
axillary lymph nodes judged to be disease free after routine
histological examination revealed micrometastases in 83 (9%) of
921 breast cancer patients. These patients had a poorer disease-free
(P¼0.003) and overall (P¼0.002) survival after 5 years’ median
follow-up than did patients whose nodes remained negative on
serial sectioning. A later study performed by the same group (Cote
et al, 1999) examined lymph nodes negative for metastases on
routine histology from 736 patients by serial sectioning and by
immunohistochemistry (IHC) with two anticytokeratins AE-1 and
CAM 5.2. Occult nodal metastases were detected by serial
sectioning and H&E in 7% of the patients and by IHC in 20%.
After median follow-up of 12 years, occult metastases, detected by
either method, were associated with significantly poor disease-free
and overall survival in postmenopausal but not in premenopausal
patients. Other studies have also shown that breast cancer
micrometastases in axillary lymph nodes being detected by serial
sectioning and IHC have prognostic significance (Braun et al, 2000,
2001). Reverse transcriptase–polymerase chain reaction (RT–
PCR) has a potential of increasing the sensitivity of the pathologic
processing of lymph nodes obtained from breast cancer patients.
However, the specificity of RT–PCR is lower as compared to IHC
and the prognostic significance of breast cancer micrometastases
detected by RT–PCR is yet to be determined. Studies in malignant
melanoma patients showed that detection of mRNA of the enzyme
tyrosinase by RT–PCR reaction in sentinel lymph nodes (SLN)
correlates with disease recurrence and survival (Shivers et al, 1998;
Li et al, 2000). Several studies utilised mRNA detection by RT–
PCR to detect minimal residual disease (MRD) in breast cancer
patients (Schoenfeld et al, 1994; Noguchi et al, 1996; Aihara et al,
1999; Inokuchi et al, 2003). Different mRNA markers and RT–PCR
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stechniques were used for the detection of breast cancer micro-
metastases and therefore results vary between investigators.
Epithelial nonspecific markers such as cytokeratin (CK)-19 or
CK-20 are present on every breast cancer cell but the risk of
contamination by noncancer epithelial cells during surgery exists.
Small amounts of CK were reported to be expressed in interstitial
reticulum cells present in normal lymph nodes (Gould et al, 1995).
Using epithelial mRNA markers carries a risk of false-positive
results. Cancer-related mRNA markers are more specific but are
not uniformly expressed in all tumours and therefore the risk of
false-negative results exists. Thus, a combination of both epithelial
and cancer-specific mRNA markers could potentially yield the
most reliable results.
However, enhanced pathologic examination of multiple lymph
nodes requires substantial resources and is time consuming.
Therefore, sentinel lymph node biopsy which replaced routine
axillary lymph node dissection (ALND) in breast cancer patients
allows the pathologist to examine one or two lymph nodes in more
detail as compared to an ALND specimen containing multiple
lymph nodes. The ability of this surgical technique to locate the
first lymph node that drains the tumour and therefore most likely
to harbor occult metastases is of great value for the detection of
micrometastatic disease.
The aim of the present study was develop an accurate
multimarker RT–PCR assay for the detection of MRD in sentinel
nodes of breast cancer patients. We elected to use two specific
mRNA markers mammaglobin-B (MGB-2 and NY-BR-1) highly
expressed in breast cancer (Becker et al, 1998; Jager et al, 2001)
combined with CK-19.
PATIENTS AND METHODS
Twenty-eight patients with histologically confirmed primary
adenocarcinoma of the breast underwent sentinel lymphadenec-
tomy performed by a single attending surgeon at Hadassah-Hebrew
University Hospital Mount Scopus. Patients with clinical lymph node
involvement or distant metastases were excluded from the study.
Operative technique
Unfiltered technetium Tc 99m sulphur colloid was injected around
the primary lesion or biopsy site 2–24h before surgery.
Preoperative lymphoscintigraphy was performed prior to surgery,
once the sentinel node was visualised, the patients were transferred
to the operating room. Vital blue dye was injected at the site of the
primary tumour. Using a handheld gamma probe (Neoprobe
2000
s, Neoprobe Inc., Dublin, OH, USA), the sentinel lymph node
was localised identified and excised.
Sentinel lymph node processing
In all, 30 SLN specimens were submitted fresh from the operating
room in a sterile fashion. Each SLN was bivalved, one-half of each
specimen was formalin fixed and paraffin embedded for standard
pathologic examination, and the remainder of the SLN was snap
frozen in liquid nitrogen for subsequent molecular analysis by
RT–PCR. Multiple formalin-fixed, paraffin-embedded, H&E-
stained sections were examined. Immunohistochemistry stains
with two anticytokeratin antibodies AE-1 and CAM 5.2 were
performed.
RNA extraction
Frozen samples were powdered in dry ice, homogenised using a
Polytron homogeniser in TriReagent (Molecular Research Center
Inc., Cincinnati, OH, USA) and processed according to the
manufacturer’s instructions.
Reverse transcription–polymerase chain reaction
Reverse transcription was performed on 1–5mg RNA, using
Superscript II RNase H-Reverse Transcriptase (Invitrogen, Carls-
bad, CA, USA) and random hexamer primers (Roche, Mannheim,
Germany).
Subsequently, PCR was performed on 1/10th of the cDNA
reaction volume with the corresponding primers and at the
appropriate conditions.
Oligonucleotide primers and probes
Oligonucleotide primers and internal probes were synthesised at
MWG-Biotech AG (Ebersberg, Germany). Each set of primers
specifically amplified and detected, respectively, a 462bp fragment
of the CK-19 gene, a 245bp fragment of mammaglobin-B (MGB-2)
and a 573bp fragment of NY-BR-1. The sequence of these
oligonucleotides is as follows:
CK-19 (corresponding gene is KRT19):
CK-19F 50GAGGTGGATTCCGCTCCCCA30
CK-19R 50CTGCTCGAGGGACAGGAAGAT30
CK-19P CCTGGTTCACCAGCCGGACTGAAGAATT-
GAACCGGG
Mammaglobin B (corresponding gene is SCGB2A1):
MGB-2F 50ACTCCTGGAGGACATGGTTGA30
MGB-2R 50TCTGAGCCAAACGCCTTGGGT 30
MGB-2P GTGATGCCGCTGCAGAGGCTCTGGGGAAATT-
CAAGC
NY-BR-1 (corresponding gene is ANKRD30A):
NYBR1A 50CAAAGCAGAGCCTCCCGAGAAG30
NYBR1B 50CCTATGCTGCTCTTCGATTCTTCC30
To confirm the synthesis of cDNA, all samples were amplified
with a set of primers resulting in a 542bp fragment of the RNF38
gene:
Housekeeping gene RNF38 (corresponding gene is RNF38):
RNF38F 50AAAAAGTCTTTGGAGTTCCATCAC30
RNF38R 50GAAGATGGAGAAGTAGAAAATTAC30
DNA amplification
Independent amplification reactions were performed with the
different primer sets. Cytokeratin-19 and NY-BR-1 were amplified
in a 50ml reaction mixture containing 5pmol of both primers,
2m M MgCl2, 200mmoll
 1 of each deoxyribonucleoside triphos-
phate, and 2.5U of the recombinant FastStart Taq DNA Poly-
merase in 1 GC-RICH solution (Roche, Mannheim, Germany).
Negative and positive controls were amplified in every experiment,
as well as samples devoid of DNA. Polymerase chain reaction was
performed in a DNA thermal cycler (MJ Research, Watertown, MA,
USA). To ensure full denaturation, the mixtures were heated at
941C for 4min, followed by 40 and 30 amplification cycles,
respectively, of 45s at 941C, 40s at 581C, and 45s at 721C. MGB-2
was amplified in the same reaction mixture for 40 cycles at the
same conditions except for annealing carried out at 551C for 30s
and extension at 721C for 1min. RNF38 was amplified with
Amplitaq polymerase (Roche, Mannheim, Germany) for 30 cycles
at 941C for 45s, 521C for 30s and 721C for 1min. An additional
5min elongation at 721C was included for all amplifications. For
analysis of PCR products 10ml of the amplification products were
electrophoresed on a 2% agarose gel (BMA, Rockland, MA, USA)
and visualised by ultraviolet illumination after ethidium bromide
staining.
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Southern blot of the PCR products was performed on a Genescreen
Plus membrane in 20 SSC. Hybridisation was performed in
Rapid-hyb buffer (Amershampharmacia biotech, Piscataway, NJ,
USA) with oligonucleotide probes (CK-19P and MGB-2P) pre-
viously biotin labelled by biotin N
6-ddATP (10pmolml
 1, NEN
Life Science Products Inc., Boston, MA, USA). Detection was
carried out following incubation with streptavidin–HRP conjugate
and visualised by chemiluminescence (NEN Life Science Products
Inc., Boston, MA, USA) according to the instructions of the
manufacturer.
Data analysis
Summary statistics were obtained using established methods.
Differences between categorical variables were calculated using
either w
2 test or Fisher’s exact test as appropriate. A P-value o0.05
was considered to be significant. Statistical analysis was performed
with SPSS
s version 10 for Windows statistical package (SPSS Inc.,
Chicago, IL, USA).
RESULTS
In all, 30 SLNs from 28 patients were studied. RNA was extracted
and cDNA synthesised successfully from all 30 SLNs. The presence
of cDNA in all samples was confirmed by PCR with a set of primers
which amplifies a 542bp segment of the RNF38 ubiquitously
expressed gene (data not shown).
Enhanced pathologic analysis by H&E detected breast cancer
metastasis in 6/30 nodes (20.0%) and IHC for CK was positive in
the same six nodes and in two additional lymph node (8/30,
26.7%). Reverse transcriptase–polymerase chain reaction for at
least one of the three markers was positive in 15/30 nodes (50.0%)
including all nodes positive by IHC and seven additional nodes.
These results are outlined in Table 1 and Figure 1.
The sensitivity of IHC for CK in the detection of breast cancer
micrometastases in SLNs was increased by 6.7% as compared to
the H&E stain alone. Reverse transcriptase–polymerase chain
reaction increased sensitivity in additional 23.3% compared to
combined H&E and IHC stains and by 30.0% as compared to H&E
alone (Table 2).
All three markers were highly expressed in 5/6 (83.3%) H&E-
positive SLNs. In one patient where SLN was positive both by H&E
and IHC, only MGB-2 and NY-BR-1 were expressed while RT–PCR
for CK-19 was negative (case # 28, Table 1).
Reverse transcriptase–polymerase chain reaction was positive
for all three markers in 7/15 (46.7%) of positive SLNs, for two
markers in 3/15 (20%) of positive SLNs, and for a single marker in
5/15 (33.3%) of positive SLNs.
Reverse transcriptase–polymerase chain reaction was positive
for CK-19, in 8/30 (26.7%) SLNs, for MGB-2, in 11/30 (36.6%)
SLNs, and for NY-BR-1, in 13/30 (43.3%) patients (Table 3).
Three primary tumours of breast cancer patients were used as
positive controls. All three tumours showed strong amplification
for all three markers (Figure 1). Lymph nodes of three patients
with benign lymphadenopathy biopsied for diagnostic purposes
(reactive lymph nodes by histology without evidence of malig-
nancy) and peripheral blood lymphocytes of 10 healthy volunteers
were used as negative controls. None of the 13 negative control
specimens were amplified by any of the three RT–PCR markers
used in the study.
Southern blot
In order to verify the RT–PCR results, Southern blot was
performed for CK-19 and MGB-2. A probe for NY-BR-1 was
constructed but failed to show any significant staining, therefore
we elected to confirm the RT–PCR results by CK-19 and MGB-2
only. The results are outlined in Table 1. There was no difference
between the Southern blot results and the RT–PCR results for both
markers.
Table 1 Analysis of sentinel lymph nodes for the presence of breast
cancer metastases by H&E, IHC and RT–PCR
CK-19 NY-BR-1 MGB-2
H&E IHC RT–PCR SB RT–PCR SB
a RT–PCR SB
1   ++
a ++
a
2   ++
a +  
a
3    +++ + + + + +
4            
5            
6        +   
7 + + +++ + +
8 + + +++ + +++ +++ +
9         ++
10            
11            
12            
13            
14            
15         ++
16            
17        +   
18        +   
19            
20            
21        ++ ++ ++
2 2 + + +++ + ++
23            
24            
25            
26 + + +++ + +++ +++ +
27 + + +++ + +++ +++ +
28 + +   ++ + +
29            
30            
aSouthern blot was not performed due to technical reasons. H&E¼haematoxilyn
and eosin stain; IHC¼immunohistochemistry stain for cytokertain; RT–PCR¼re-
verse transcriptase–polymerase chain reaction; CK-19¼cytokeratin-19; MGB-
2¼mammaglobin-2; SB¼southern blot.
CK-19
MGB-2
NY-BR-1 573 bp
245 bp
462 bp
12 3 4 5 6 7 8 9 1 0 1 1 1 2
SLN LN PBL TU
Figure 1 Gel electrophoresis of PCR products of the three molecular
markers. Five representative sentinel lymph nodes (SLN) were chosen and
amplified again for demonstration of the three markers used in the study:
cytokeratin-19 (CK-19), mammaglobin-2 (MGB-2) and NY-BR-1. All five
SLNs showed amplification of all three markers (lanes #1–5). Representa-
tive negative controls including one lymph node obtained from a patient
with disease other than breast cancer (LN, lane #6) and peripheral blood
lymphocytes obtained form healthy volunteers (PBL, lanes #7–9). Three
primary tumours were used as positive controls (TU, lanes #10–12).
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Diagnosis and staging of malignant diseases using molecular
biology techniques focused initially on the analysis of the primary
tumour. Despite large amount of data showing relationship
between molecular findings and patient’s outcome, very few
molecular biology techniques are being used in routine clinical
practice. The search for MRD in sites other than the primary
tumour such as lymph nodes, bone marrow or peripheral blood is
a different direction of utilising sensitive molecular biology
techniques for cancer staging and improving treatment selection.
The ideal molecule for MRD detection would be a molecule
expressed in all tumour cells but not in normal human tissues.
Such molecules are rare and most of the investigators focus on
molecules expressed in tumour and normal tissues but not
expressed in the target organ. Such an example is the utilisation
of tyrosinase, an enzyme present only in melanocytes, for the
detection of MRD in melanoma patients (Li et al, 2000). In breast
cancer patients, molecules such as CK, expressed in epithelial cells
but not expressed in lymphocytes, were investigated (Kruger et al,
1996; Manhani et al, 2001; Ismail et al, 2003). Using PCR to detect
nonspecific epithelial markers may yield a robust and simple assay
for the detection of MRD in patients with epithelial-derived
tumours. However, the risk of false-positive results due to
contamination by epithelial cells during the surgical procedure is
high. On the other hand, tumour-specific molecular markers are
not uniformly expressed in all tumours and therefore if tumour
tissue is not available for analysis or the selected marker is not
expressed, the assay will be inconclusive.
In the present study, we elected to combine a nonspecific
epithelial marker (CK-19) with breast cancer-specific markers
(MGB, NY-BR-1) in order to achieve high sensitivity in MRD
detection.
Our results show that the addition of immunohistochmical
staining of the SLN for CK increased the SLN positivity rate from
20 to 26.7%. This is well within the range reported in the literature
(Euhus, 2003; Chao, 2004). Staging by RT–PCR increased the
number of positive SLN from 20 to 50% when any positive marker
is considered. All three molecular markers were positive in all
three primary tumour tissues and negative in all 13 negative
controls. However, if only SLNs with all three molecular markers
were considered positive we would have missed one of the six
H&E-positive SLNs and one of the two IHC-only-positive SLNs.
One additional SLN would have been considered positive. When
any two molecular markers were considered positive, all H&E- and
IHC-positive SLNs with additional two SLNs would have been
positive by RT–PCR.
A single molecular marker was positive in 50% of the SLNs, the
significance of a positive single molecular marker is yet to be
determined. The most sensitive molecular marker was NY-BR-1
being positive in 13 SLNs, followed by MGB-2 in 12 SLNs and CK-
19 in eight. Interestingly, the two specific markers were more
sensitive compared to the epithelial marker (CK-19), which is
expected to yield a certain degree of false-positive results due to
contamination by epithelial cells at the time of surgery. This can
be explained by the surgical technique used in the present study
where careful attention was paid not to use contaminated
instruments to handle the SLN. Mammaglobin was studied before
by other investigators, (Ouellette et al, 2004) who examined the
expression of MGB-1and -2 in 22 SLNs from breast cancer patients.
They found a sensitivity of 88% and specificity of 72% as
compared to the histological status. Other investigators (Ooka
et al, 2000) studied several markers in non-SLNs from 17 breast
cancer patients. In their study, prostate-specific antigen (PSA),
carcinoembryonic antigen (CEA), and MGB-1 and -2 were highly
expressed in the primary tumours. Mammaglobin-1 and -2 were
100% positive in the H&E-positive lymph nodes while CEA and
PSA were positive in 35.7 and 57.1% of the H&E-positive lymph
nodes. Mammaglobin-1 and -2 were amplified in additional 30.1
and 17.8% of the H&E-negative nodes. In an interim analysis of
a multi-institutional study of multimarker RT–PCR of H&E-
negative lymph nodes (Gillanders et al, 2004), a correlation
between PCR positivity and other well-established prognostic
markers including histological grade and St Gallen risk category
was reported. This study also showed mammaglobin to be the most
informative marker in their multimarker panel.
Our results with MGB-2 are close to results reported by others.
Our results show that multimarker RT–PCR is more sensitive as
compared to the standard pathologic processing of the SLN by
serial sections and IHC and that a multimarker approach is much
more sensitive as compared to any single marker. NY-BR-1 was
more sensitive than MGB-2 and the only molecular marker
positive in all H&E- and IHC-positive nodes. Despite its high
sensitivity, NY-BR-1 is not uniformly expressed in all breast
cancers and since fresh primary tumour tissue is not always
available for molecular analysis, it could not be used as a single
marker. In the future, when anti-NY-BR-1 antibodies will be
available, its expression on the primary tumour cells could be
determined by IHC and when expressed, it can be used as a single
molecular marker in the NY-BR-1-positive tumours. Until then, a
multimarker assay would be the best choice for the determination
of MRD in node-negative breast cancer patients. The significance
of MRD detected by RT–PCR in SLNs of breast cancer patients is
yet to be determined. The current AJCC-UICC staging system
defines micrometastasis as tumour deposits of o2mm in diameter
and cell clusters as tumour cells within the lymph node with a
Table 2 Comparison of different detection methods for breast cancer sentinel lymph-node metastases
Method Total positive % Positive
a Absolute sensitivity increase (%) Relative sensitivity increase
b (%)
H&E 6 20.0 0 0
IHC 8 26.7 6.7 33.3
RT–PCR 15 50.0 30.0 150.0
aPercentage of positive nodes out of all nodes analysed (N¼30).
bPercentage increase in positive nodes detected using number of nodes detected by H&E as a baseline (N¼6).
H&E¼haematoxilyn and eosin stain; IHC¼immunohistochemistry stain for cytokertain; RT–PCR¼reverse transcriptase–polymerase chain reaction.
Table 3 Increment sensitivity of SLN analysis for breast cancer
metastases
Frequency of
positive SLN
Percentage of
positive SLN (%) P-value*
H&E 6 20
IHC 8 26.7 o0.01
NY-BR-1 13 43.3 o0.01
CK-19 8 26.7 o0.01
MGB-2 11 36.7 o0.01
3 markers 7 23.3 o0.01
2 markers 10 33.3 o0.01
1 marker 15 50.0 o0.01
*Fisher’s exact test two-tailed P-value (compared to H&E alone). SLN¼sentinel
lymph node; H&E¼haematoxylin and eosin stain; IHC¼immunohistochemistry stain
for cytokeratin.
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their detection (Singletary et al, 2003). Controversy exists not only
regarding the management of breast cancer patients with
micrometastasis but also regarding patients with macrometastasis
detected in the SLN. The management of breast cancer patients
with macroscopic SLN metastasis is currently investigated in two
prospective randomised clinical trials, the EORTC 10981-22023
(AMAROS) trial and the ACOSOG Z011(Mansel and Goyal, 2004;
Posther et al, 2004). Both trials comparing axillary lymph node
dissection to radiation therapy (AMAROS) and to no further
surgery (Z011) in T1–T2 breast cancer patients with positive SLN.
Two other clinical trials, the IBCSG 23-01 trial and the ACOSOG
Z010 (Mansel and Goyal, 2004; Posther et al, 2004) are studying the
significance of micrometastasis detected by either IHC or H&E in
SLN of breast cancer patients. The significance of RT–PCR in
molecular staging of breast cancer will be determined not only by
these ongoing clinical trials but also by future large-scale
prospective trials stratifying patients according to the volume of
metastatic disease in the SLN.
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